Delta-globin gene expression improves sickle cell disease in a humanised mouse model.
delta-globin
haemoglobin A2
humanised mouse model
sickle cell disease
transgenic mouse
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
09
04
2021
received:
04
02
2021
accepted:
19
04
2021
pubmed:
29
5
2021
medline:
28
9
2021
entrez:
28
5
2021
Statut:
ppublish
Résumé
Sickle cell disease (SCD) is a widespread genetic disease associated with severe disability and multi-organ damage, resulting in a reduced life expectancy. None of the existing clinical treatments provide a solution for all patients. Gene therapy and fetal haemoglobin (HbF) reactivation through genetic approaches have obtained promising, but early, results in patients. Furthermore, the search for active molecules to increase HbF is still ongoing. The delta-globin gene produces the delta-globin of haemoglobin A2 (HbA2). Although expressed at a low level, HbA2 is fully functional and could be a valid anti-sickling agent in SCD. To evaluate the therapeutic potential of a strategy aimed to over-express the delta-globin gene in vivo, we crossed transgenic mice carrying a single copy of the delta-globin gene, genetically modified to be expressed at a higher level (activated), with a humanised mouse model of SCD. The activated delta-globin gene gives rise to a consistent production of HbA2, effectively improving the SCD phenotype. For the first time in vivo, these results demonstrate the therapeutic potential of delta-globin, which could lead to novel approaches to the cure of SCD.
Substances chimiques
delta-Globins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1228-1237Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 British Society for Haematology and John Wiley & Sons Ltd.
Références
Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376:1561-73.
Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390:311-23.
Mburu J, Odame I. Sickle cell disease: reducing the global disease burden. Int J Lab Hematol. 2019;41(Suppl 1):82-8.
Houwing ME, de Pagter PJ, van Beers EJ, Biemond BJ, Rettenbacher E, Rijneveld AW, et al. Sickle cell disease: clinical presentation and management of a global health challenge. Blood Rev. 2019;37:100580.
McGann PT. Time to invest in sickle cell anemia as a global health priority. Pediatrics. 2016;137:e20160348.
Cisneros GS, Thein SL. Recent advantages in the treatment of sickle cell disease. Front Physiol. 2020;11:435.
Gluckman E, Cappelli B, Bernaudin F, Labopin M, Volt F, Carreras J, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129:1548-56.
Arnold SD, Bhatia M, Horan J, Krishnamurti L. Haematopoietic stem cell transplantation for sickle cell disease - current practice and new approaches. Br J Haematol. 2016;174:515-25.
Orkin SH, Bauer DE. Emerging genetic therapy for sickle cell disease. Annu Rev Med. 2019;70:257-71.
Esrick EB, Bauer DE. Genetic therapies for sickle cell disease. Semin Hematol. 2018;55:76-86.
Magrin E, Miccio A, Cavazzana M. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies. Blood. 2019;134:1203-13.
Telen MJ, Malik P, Vercellotti GM. Therapeutic strategies for sickle cell disease: towards a multi-agent approach. Nat Rev Drug Discov. 2019;18:139-58.
Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376:848-55.
Forget BG. Molecular basis of hereditary persistence of fetal hemoglobin. Ann NY Acad Sci. 1998;850:38-44.
Thein SL. Genetic basis and genetic modifiers of β-thalassemia and sickle cell disease. Adv Exp Med Biol. 2017;1013:27-57.
Steinberg MH. Fetal hemoglobin in sickle hemoglobinopathies: high HbF genotypes and phenotypes. J Clin Med. 2020;9:3782.
Lavelle D, Engel JD, Saunthararajah Y. Fetal hemoglobin induction by epigenetic drugs. Semin Hematol. 2018;55:60-7.
Esrick EB, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF, et al. Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. N Engl J Med. 2021;384:205-15.
Frangoul H, Altshuler D, Cappellini MD, Chen Y-S, Domm J, Eustace BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384:252-60.
Steinberg MH, Rodgers GP. HbA2: biology, clinical relevance and a possible target for ameliorating sickle cell disease. Br J Haematol. 2015;170:781-7.
Nagel RL, Bookchin RM, Johnson J, Labie D, Wajcman H, Isaac-Sodeye WA, et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci USA. 1979;76:670-2.
Adachi K, Pang J, Reddy LR, Bradley LE, Chen Q, Trifillis P, et al. Polymerization of three hemoglobin A2 variants containing Val6 and inhibition of hemoglobin S polymerization by hemoglobin A2. J Biol Chem. 1996;271:24557-63.
Steinberg MH, Adams JG 3rd. Hemoglobin A2: origin, evolution, and aftermath. Blood. 1991;78:2165-77.
Wu LC, Sun CW, Ryan TM, Pawlik KM, Ren J, Townes TM. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood. 2006;108:1183-8.
Manchinu MF, Marongiu MF, Poddie D, Casu C, Latini V, Simbula M, et al. In vivo activation of the human δ-globin gene: the therapeutic potential in β-thalassemic mice. Haematologica. 2014;99:76-84.
Torrance JD, Bothwell TH. A simple technique for measuring storage iron concentrations in formalinised liver samples. S Afr J Med Sci. 1968;33(1):9-11.
Wu CJ, Krishnamurti L, Kutok JL, Biernacki M, Rogers S, Zhang W, et al. Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood. 2005;106:3639-45.
Ben Khaled M, Ouederni M, Mankai Y, Rekaya S, Ben Fraj I, Dhouib N, et al. Prevalence and predictive factors of splenic sequestration crisis among 423 pediatric patients with sickle cell disease in Tunisia. Blood Cells Mol Dis. 2020;80:102374.
Nguyen J, Abdulla F, Chen C, Nguyen P, Nguyen M, Tittle B, et al. Phenotypic characterization the Townes sickle mice. Blood. 2014;124:4916.
Manchinu MF, Simbula M, Caria CA, Musu E, Perseu L, Porcu S, et al. Delta-globin gene expression is enhanced in vivo by interferon type I. Front Med (Lausanne). 2020;7:163.
Powars DR, Weiss JN, Chan LS, Schroeder WA. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood. 1984;63:921-6.
Steinberg MH, Chui DH, Dover GJ, Sebastiani P, Alsultan A. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood. 2014;123:481-5.
Estepp JH, Smeltzer MP, Kang G, Li C, Wang WC, Abrams C, et al. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. Am J Hematol. 2017;92:1333-9.
Coleman MB, Adams JG 3rd, Plonczynski MW, Harrell AH, Walker AM, Fairbanks V, et al. Beta-thalassemia intermedia with exceptionally high hemoglobin A2: relationship to mutations in the beta-gene promoter. Am J Med Sci. 1992;304:73-8.
Ozcan ME, Ince B, Karadeli HH, Gedikbasi A, Asil T, Altinoz MA. Higher minor hemoglobin A2 levels in multiple sclerosis patients correlate with lesser disease severity. Neuropsychiatr Dis Treat. 2016;12:2033-8.